ABSTRACT
BACKGROUND: Despite metabolic disorders in HIV-infected children being widely described, there is still a lack of agreed criteria for diagnoses and management. Numerous studies are coming from other settings and results are heterogeneous when assessing several analytical and clinical parameters. OBJECTIVES: To describe the prevalence of metabolic disorders and associated risk factors in the Spanish National cohort of HIV-infected pediatric patients (CoRISpe). METHODS: This was a cross-sectional study following all vertically HIV-infected children and adolescents in three referral centers included in the CoRISpe. Metabolic data (fasting lipids, glucose and insulin levels and thyroid hormone levels) were collected. Fat distribution was clinically assessed by expert clinicians. RESULTS: We included 157 patients [median age 13 years, interquartile range (IQR) 10-16]. Median duration of antiretroviral therapy was 10.2 years (IQR 5.0-13.0). Almost 20% of patients had insulin resistance and this was associated with hepatitis C co-infection, current use of stavudine (d4T) and hypertriglyceridemia. Hypercholesterolemia and hypertriglyceridemia were found in 23.9% and 24.8% of patients and were associated with current use of protease inhibitors (p = 0.042 and p = 0.022, respectively). Abnormal fat distribution was observed in 63 patients (40.5%): lipoatrophy in 32 (20.4%), lipohypertrophy in eight (5.1%) and a mixed pattern in 23 patients (14.6%), and it was significantly associated with previous exposure to stavudine (p < 0.001). CONCLUSIONS: Metabolic disorders are a significant problem in our HIV-infected pediatric population. We need to encourage the development of global strategies and the creation of consensus guidelines that can decrease the cardiovascular risk in this population.
Subject(s)
Cardiovascular Diseases/epidemiology , HIV Infections/epidemiology , HIV Infections/transmission , Infectious Disease Transmission, Vertical/statistics & numerical data , Metabolic Diseases/epidemiology , Adolescent , Adult , Child , Cross-Sectional Studies , Dyslipidemias/epidemiology , Female , Humans , Insulin Resistance , Male , Multivariate Analysis , Risk FactorsABSTRACT
Visceral leishmaniasis is a severe form of infection caused by a parasite endemic along the Mediterranean coast. Complications such as infection-associated hemophagocytic syndrome can occur despite correct therapy. We report visceral leishmaniasis-associated infection-associated hemophagocytic syndrome in 3 patients with chronic granulomatous disease.
Subject(s)
Granulomatous Disease, Chronic/complications , Leishmaniasis, Visceral/complications , Lymphohistiocytosis, Hemophagocytic/complications , Adolescent , Amphotericin B/therapeutic use , Animals , Antiprotozoal Agents/therapeutic use , Child , Fatal Outcome , Female , Humans , Interferon-gamma/therapeutic use , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/drug therapy , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/etiology , Male , Recombinant ProteinsABSTRACT
During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.
Subject(s)
Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Leishmaniasis, Visceral/drug therapy , AIDS-Related Opportunistic Infections/prevention & control , Amphotericin B/administration & dosage , Amphotericin B/economics , Amphotericin B/pharmacokinetics , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/pharmacokinetics , Clinical Trials as Topic , Drug Carriers , Drug Costs , Health Planning Guidelines , Humans , Liposomes , Treatment OutcomeABSTRACT
We describe 3 siblings with interleukin-12 receptor beta1 (IL-12Rbeta1) deficiency, a known genetic etiology of clinical disease caused by infection with poorly virulent mycobacteria, such as mycobacteria found in bacille Calmette-Guérin (BCG) vaccines and environmental nontuberculous mycobacteria (NTM). One child had disseminated tuberculosis, the second had extraintestinal salmonellosis and pulmonary tuberculosis, and the third remained asymptomatic. IL-12Rbeta1 deficiency should be considered as a diagnosis in patients with severe salmonellosis or tuberculosis, even if they do not have disease due to BCG or NTM.
Subject(s)
Mycobacterium , Receptors, Interleukin/deficiency , Tuberculosis/metabolism , Adolescent , BCG Vaccine , Child , Child, Preschool , Female , Humans , Infant , Receptors, Interleukin/genetics , Receptors, Interleukin/metabolism , Receptors, Interleukin-12 , Salmonella Infections/genetics , Salmonella Infections/metabolism , Salmonella Infections/physiopathology , Tuberculosis/genetics , Tuberculosis/physiopathologyABSTRACT
Acute bacterial sinusitis is usually a clinical diagnosis. Orbital complications require emergent evaluation with computed tomography. Using the orbital septum as an anatomic landmark, such infections can be classified as pre- or postseptal and treated with the most adequate therapy, ie, oral or intravenous antibiotics or surgical endonasal drainage. Intracranial complications can be seen in 3.7% to 11% of these patients, often with subtle clinical symptoms and signs. Radiologists play a decisive role in the final management of these patients and should be familiar with the most relevant complications. In this article, we present a retrospective review of all pediatric patients referred to our department for paranasal sinuses and orbital computed tomography because of acute complicated bacterial sinusitis. They were studied with an emergent enhanced facial and cranial computed tomography within 24 hours of admission, followed by magnetic resonance imaging when intracranial complications were suspected. Particular emphasis is placed on the imaging algorithm and the most relevant complications; we correlate imaging findings with clinical and bacteriological data.
Subject(s)
Orbital Diseases/diagnostic imaging , Sinusitis/diagnostic imaging , Tomography, X-Ray Computed , Acute Disease , Adolescent , Child , Female , Humans , Male , Orbital Diseases/etiology , Orbital Diseases/microbiology , Paranasal Sinuses/pathology , Retrospective Studies , Sinusitis/complications , Sinusitis/microbiologyABSTRACT
Regular screening methods may miss the diagnosis of occult hepatitis B infection and seronegative hepatitis C virus infection in immunocompromised patients. A cross-sectional study within a Spanish cohort of HIV-infected children yielded 6 of 254 (2.4%) possible occult hepatitis B infection cases and 2 of 254 (0.8%) seronegative hepatitis C virus-infected patients. Implementation of occult hepatitis screening in the routine care of these children may be warranted.
Subject(s)
HIV Infections/complications , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Mass Screening/methods , Adolescent , Child , Cohort Studies , Cross-Sectional Studies , Female , Hepatitis B/epidemiology , Hepatitis C/epidemiology , Humans , Male , Prevalence , Spain/epidemiologyABSTRACT
The impact of Chagas disease is no longer restricted to endemic areas. The aim of this study is to evaluate a 2-year period of a vertical transmission screening program of Trypanosoma cruzi infection in a tertiary care hospital in Barcelona (Spain). Two enzyme-linked immunosorbent assays (recombinant and crude antigen) were performed in parallel to pregnant women at risk of T. cruzi infection. Discordant results were confirmed by a third diagnostic test. In the case of a positive result, the newborn was tested at birth and after 8 months of life. A total of 1,473 women met the inclusion criteria for the screening program with a resulting seroprevalence for T. cruzi of 3.5% (2.2-5.2% 95% confidence interval [95% CI]). One case of congenital infection was identified. Screening programs for vertically transmitted T. cruzi acute infection are beneficial in non-endemic areas for early detection and treatment of acute infection.
Subject(s)
Tertiary Care Centers/organization & administration , Trypanosoma cruzi/isolation & purification , Trypanosomiasis/congenital , Disease Transmission, Infectious , Enzyme-Linked Immunosorbent Assay , Female , Humans , Infant, Newborn , Male , Pregnancy , Spain , Trypanosomiasis/diagnosis , Trypanosomiasis/parasitology , Trypanosomiasis/transmissionSubject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Pyridines/therapeutic use , Pyrones/therapeutic use , Child , Drug Resistance, Multiple, Viral , Drug Therapy, Combination , HIV Protease/genetics , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/blood , HIV Protease Inhibitors/pharmacology , HIV Reverse Transcriptase/genetics , HIV Wasting Syndrome/drug therapy , HIV-1/drug effects , HIV-1/enzymology , HIV-1/genetics , Humans , Male , Mutation , Pyridines/administration & dosage , Pyridines/blood , Pyridines/pharmacology , Pyrones/administration & dosage , Pyrones/blood , Pyrones/pharmacology , Ritonavir/administration & dosage , Ritonavir/therapeutic use , Sulfonamides , Viral LoadABSTRACT
Acute mastoiditis is a serious complication of acute otitis media in children. Suppurative disease in the mastoid region occasionally spreads to the adjacent dura mater of the posterior and middle cranial fossae and the sigmoid sinus by means of thrombophlebitis, osseous erosion, or anatomic pathways, producing intracranial complications. Computed tomography (CT) should be performed early in the course of the disease to classify the mastoiditis as incipient or coalescent and to detect intracranial complications. On the basis of the clinical features and imaging findings, the disease is managed conservatively with intravenously administered antibiotics or treated with mastoidectomy and drainage plus antibiotic therapy. CT is therefore a decisive diagnostic tool in determining the type of therapy. In addition, magnetic resonance imaging is performed in patients with clinical symptoms or CT findings suggestive of intracranial complications because of its higher sensitivity for detection of extraaxial fluid collections and associated vascular problems.